|Mr. Fabio Chianelli||CEO & Chairman||172.52k||N/A||1978|
|Mr. Carmelo Marrelli ACIS, B.Comm., CA, CGA, CPA||Chief Financial Officer||88.21k||N/A||1971|
|Mr. Andrew Todd||Corp. Sec.||N/A||N/A||1958|
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine injectables/infusions, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase II clinical trial for treating depression; and Ketamine Pump, which is in Phase II clinical trial to treat complex regional pain syndrome, metal health, neurological, and pain disorders. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. PharmaTher Holdings Ltd has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; and Revive Therapeutics Ltd. to develop psilocybin microneedle patch. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
PharmaTher Holdings Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.